Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.47 |
| ▸ | CXCR3 | P49682 | 5/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | RHOC | P08134 | 1/20 | 0.37 |
| ▸ | RHOA | P61586 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6863510 | 0.88 | EPHX2 (0.45) | EPHX2CXCR3GAARHOCRHOA | |
| SCHEMBL6862576 | 0.86 | EPHX2 (0.44) | EPHX2CXCR3GAARHOCRHOA | |
| SCHEMBL6863250 | 0.86 | EPHX2 (0.62) | EPHX2CXCR3CYP2D6 | |
| SCHEMBL12014289 | 0.84 | MGLL (0.46) | EPHX2CXCR3GAARHOCRHOA | |
| SCHEMBL12005298 | 0.79 | S1PR2 (0.44) | EPHX2 | |
| SCHEMBL12015274 | 0.78 | LMNA (0.40) | EPHX2CYP2D6 | |
| SCHEMBL14433885 | 0.77 | MAPT (0.55) | EPHX2CXCR3USP30KCNH2CACNA1I | |
| SCHEMBL6863316 | 0.77 | CXCR3 (0.46) | EPHX2CXCR3USP30KCNH2CACNA1I | |
| SCHEMBL6863377 | 0.77 | CXCR3 (0.46) | EPHX2CXCR3USP30KCNH2CACNA1I | |
| SCHEMBL4279051 | 0.75 | CXCR3 (0.44) | EPHX2CXCR3GAARHOCRHOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| WO-2011032291-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD . (CA) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | CACNA1G, CACNA1I, CACNA1H | EPHX2 3610/4885CXCR3 2678/4885USP30 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.